Member Info for OilMan1984

Long- Can you please use some basic punctuation and re-post the message below. I'm struggling to decipher your point!

The risk here is jumping ship trying to make a few quid elsewhere, the RNS drops, then you can't get back in! Will that be before month end? Nobody knows! I've held here just over 2 years, another 6-10 month wont be bothering me.

Out of interest can somebody please answer the following question......
If any of the following were to reduce their holding(s) would these have to be sold on AIM or could this be done on the Nasdaq?

Timo Kalevi Syrjälä 6,520,477 13.9%
Tom Erik Lind 3,547,712 7.58%
A&B (HK) Co. Ltd. 3,408,409 7.28%
Juho Markku Jalkanen 3,194,290 6.83%
Marko Salmi 2,817,736

The 8-12 Month news window mentioned by Marku in April is now 6 - 10 Months.

Rookie, not sure what investors expectations would be if an offer came in.......

Personally, having recently invested at just over £6 i’d gladly take £20. Please feel free to comment.

2015. Thee company announced it had taken a 55% majority stake in Acerta for $4 billion. As part of the transaction the company will gain commercial rights to Acerta's irreversible oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which is currently in Phase III development for B-cell blood cancers and in Phase I or II clinical trials in solid tumours.

What would the value be for Bexmarilimab / Clevegen? As clevegen is treating multiple cancer types i see a significantly larger value than the $4Billion majority stake in Acerta!!!!!

Thoughts anyone?

February 2015 Astrazenca, the company announced it would acquire the US and Canadian rights to Actavis' branded respiratory drug business for an initial sum of $600 million.

What would be the value of Traumakine be in the current Covid Pandemic? Double?

Even at these low oil prices RRE are still adding £££ to their war chest. The SP can only be suppressed for so long.

Look as SQZ, it’s almost back to pre covid levels. We’ve only got another 100% to go!!!

https://mondovisione.com/media-and-resources/news/nasdaq-nordic-semi-annual-review-of-the-first-north-25-index/

STOCKHOLM (News Agency Direct) Healthcare company Enzymatica belongs to the companies that will be included in the Nasdaq First North 25 index in conjunction with the half-yearly review. So does Maha Energy, the eye-tracking company Smart Eye and the real estate company Trianon.
Nasdaq said this in a press release.

Other companies included are Finnish Faron Pharmaceuticals and Finnish Remedy Entertainment.

The changes are effective from 1 July.

The 25 companies included in the index are the 25 most traded First North companies among the 30 largest First North companies, measured by market value.

https://uk.finance.yahoo.com/news/why-rockrose-energy-small-cap-082029939.html

Itsall,
Got a response back from LAGO..........

Hello Sir,
May I ask the reason behind tracking our trading activity in Faron?
Kind regards,

So ive responded that im trying to determine how may shares are still available on AIM by determining the number of shares that LAGO has transferred across to the Nasdaq since the dual listing commenced in 2019.
Daily totals sold by LAGO are readily available online however im unable to determine the cumulative total that have been traded since 2019?

No answer yet............!!

https://edition.cnn.com/2020/06/18/investing/oil-price-spike-jpmorgan/index.html

Itsall, will do mate!

Keep you updated with any info'

https://simplywall.st/stocks/gb/energy/lse-rre/rockrose-energy-shares

Debt Level: RRE is debt free.
Reducing Debt: RRE has not had any debt for past 5 years.
Debt Coverage: RRE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RRE has no debt, therefore coverage of interest payments is not a concern.

Share Price vs. Fair Value: 83.9%Undervalued

Info from Morning Star: Nothing we didn't already know so went to LAGO direct.

Please see the below feedback from our Equity data team:

0P0001FTOI /EX$$$$XBER: 4FR

We provide company level TSO which is sum of difference class of shares. For this company, only once common stock listed and no other class. In this case, share outstanding is 46,799,747. LSE listed shares are primary share.

Itsall, ive emailed LAGO this morning. Lets see what they say.

On a seperate note. Just come across this article>
https://www.springermedizin.de/covid-19/interferon-beta-1a-for-covid-19-critical-importance-of-the-admin/18078424

SNG Interferon Beta 1a inhaled getting a mention on the daily mail . We could do with similar PR.

https://www.dailymail.co.uk/news/article-8438109/Inhaler-lets-coronavirus-victims-treat-trialled-UK.html

Hi Mary,

I’ve already tried that but the website were using doesn’t allow us to trace historical data, only daily data.

Oh well, maybe i’ll drop Lago an email!!

Fear not Joe! Don’t let delinquent Dave & his possie of uneducated trolls cast doubt of negativity in your mind.

RRE is 100% the best oil stick to be invested in at the moment! Stick with it, patience will be rewarded, then the pennies will roll in.

No news tomorrow then with Helsinki being closed.

Lago have transformed just over 30k shares today on the nasdaq! Does anybody know where we can check determine the cumulative total Lago have sold on nasdaq since dual listing? Would be ingesting if we could find out that number!